Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2
2024

New Inhibitors for Parkinson's Disease Targeting LRRK2

publication

Author Information

Author(s): Raig Nicolai D., Surridge Katherine J., Sanz-Murillo Marta, Dederer Verena, Krämer Andreas, Schwalm Martin P., Elson Lewis, Chatterjee Deep, Mathea Sebastian, Hanke Thomas, Leschziner Andres E., Reck-Peterson Samara L., Knapp Stefan

Primary Institution: Cold Spring Harbor Laboratory

Hypothesis

The study investigates the development of LRRK2-selective type-II kinase inhibitors for Parkinson's disease.

Conclusion

The new type-II inhibitors stabilize the inactive conformation of LRRK2, offering potential therapeutic options for Parkinson's disease.

Supporting Evidence

  • The study presents the first LRRK2-selective type-II kinase inhibitors.
  • These inhibitors are designed to target the inactive conformation of LRRK2.
  • The inhibitors were developed using a combinatorial chemistry approach.
  • Cellular assays and cryo-electron microscopy were used to analyze the inhibitors.

Takeaway

Scientists created new medicines that can help treat Parkinson's disease by targeting a specific protein in a different way than before.

Methodology

The inhibitors were designed using a combinatorial chemistry approach and tested through cellular assays and structural analysis.

Digital Object Identifier (DOI)

10.1101/2024.09.17.613365

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication